Revance Therapeutics News

Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)

TipRanksApr 23 17:59

Goldman Sachs Maintains Neutral on Revance Therapeutics, Raises Price Target to $9

BenzingaMar 1 19:04

HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $12 Price Target

BenzingaMar 1 04:18

Revance Therapeutics Analyst Ratings

BenzingaMar 1 04:16

Analysts' Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)

TipRanksMar 1 00:01

Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating

MT NewswiresFeb 29 23:41

Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $18

BenzingaFeb 29 21:34

Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)

TipRanksFeb 29 20:11

Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)

TipRanksFeb 29 19:40

Revance Therapeutics (RVNC) Gets a Buy From Barclays

TipRanksFeb 29 15:45

Revance Therapeutics Analyst Ratings

BenzingaFeb 23 22:30

Barclays Remains a Buy on Revance Therapeutics (RVNC)

TipRanksFeb 23 16:05

Barclays Maintains Overweight on Revance Therapeutics, Lowers Price Target to $10

BenzingaJan 30 04:06

Revance Therapeutics Analyst Ratings

BenzingaJan 30 04:03

Mizuho Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $9

BenzingaJan 29 20:28

Revance Therapeutics Analyst Ratings

BenzingaJan 29 20:26

Barclays Keeps Their Buy Rating on Revance Therapeutics (RVNC)

TipRanksJan 29 18:07

Stifel Nicolaus Sticks to Their Buy Rating for Revance Therapeutics (RVNC)

TipRanksJan 12 20:37

Goldman Sachs Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $8

BenzingaJan 9 23:03

Revance Therapeutics Analyst Ratings

BenzingaJan 9 22:59